The silatecans, a novel class of lipophilic camptothecins

Bibliography

• WALL M, WANT M, COOK CE, PALMER KH, MCPHAIL HT, SIM GA: Plant antitumor agents I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Carnptotheca acurninata. J. Am. Chem. Soc. (1966) 88:3888–3890.
   Google Scholar
• WALL M: Camptothecin and taxol: discovery to clinic. Med. Res. Rev (1998) 18:299–314.
   PubMed Web of Science ®Google Scholar
• •An interesting historical account of the discovery and early development of camptothecin.
   Google Scholar
• HSIANG YH, HERTZBERG R, HECHT S, LIU L: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. (1985) 260:14873–14878.
   PubMed Web of Science ®Google Scholar
• POMMIER Y, POURQUIER P, FAN Y, STRUMBERG D: Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta (1998) 1400:83–105.
   PubMed Web of Science ®Google Scholar
• GARCIA-CARBONERO R, SUPKO JG: Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin. Cancer Res. (2002) 8:641–661.
   PubMed Web of Science ®Google Scholar
• •Detailed review with emphasis on clinical data.
   Google Scholar
• STAKER BL, HJERRILD K, FEESE MD, BEHNKE CA, BURGIN AB, STEWART L: The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc. Natl. Acad. Sd. USA (2002) 99:15387–15392.
   PubMed Web of Science ®Google Scholar
• •First X-ray crystal structure of topo I—DNA covalent complex with a bound inhibitor (TPT). Binding motif differs from the earlier models.
   Google Scholar
• HSIANG YH, LIHOU MG, LIU LF: Arrest of replication forks by drug-stabilized topoisomerase I—DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res (1989) 49:5077–5082.
   PubMed Web of Science ®Google Scholar
• SLICHENMYER WJ, ROWINSKY EK, DONEHOWER RC, KAUFMANN SH: The current status of camptothecin analogues as antitumor agents. J. Nati Cancer Inst. (1993) 85:271–291.
   PubMed Web of Science ®Google Scholar
• POTMESIL M: Camptothecins: from bench research to hospital wards. Cancer Res. (1994) 54:1431–1439.
   PubMed Web of Science ®Google Scholar
• JAXEL C, KOHN KW, WANT MC, WALL ME, POMMIER Y: Structure—activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res. (1989) 49:1465–1469.
   PubMed Web of Science ®Google Scholar
• FASSBERG J, STELLA VJ: A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogs. J. Pharm. Sci. (1992) 81:676–684.
   PubMed Web of Science ®Google Scholar
• BURKE TG, MISHRA AK, WANT MC, WALL ME: Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry (1993) 32:5352–5364.
   PubMed Web of Science ®Google Scholar
• •First in a series of papers that detail the factors involved in CPT lactone stability.
   Google Scholar
• BURKE TG, MI Z: Ethyl substitution at the 7-position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin. J. Med. Chem. (1993) 36:2580–2582.
   PubMed Web of Science ®Google Scholar
• BURKE TG, MI Z: The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J. Med. Chem. (1994) 37:40–46.
   PubMed Web of Science ®Google Scholar
• MI Z, BURKE TG: Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry (1994) 33:10325–10336.
   PubMed Web of Science ®Google Scholar
• MI Z, MALAK H, BURKE TG: Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry (1995) 34:13722–13728.
   PubMed Web of Science ®Google Scholar
• MOERTEL CG, SCHUTT AJ, REITEMEIER RJ, HAHN RG: Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemo. Rep. Part 1(1972) 56:95–101.
   PubMedGoogle Scholar
• SCOTT DO, BINDRA D, SUTTON SC, STELLA VJ: Urinary and biliary disposition of the lactone and carboxylate forms of 20 (2) -camptothecin in rats. Drug Metab. Disp. (1994) 22:438–442.
   PubMed Web of Science ®Google Scholar
• GERRITS CJ, de JONGE MJ, SCHELLENS JH, STOTER G, VERWEIJ J: Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br. J. Cancer (1997) 76:952–962.
   PubMed Web of Science ®Google Scholar
• MI Z, BURKE TG: Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency-domain fluorescence spectroscopic study. Biochemistry (1994) 33:12540–12545.
   PubMed Web of Science ®Google Scholar
• SALTZ LB: Clinical use of irinotecan: current status and future considerations. Oncologist (1997) 2:402–409.
   PubMedGoogle Scholar
• HOCHSTER H, LIEBES L, SPEYER J et al.: Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J. Gun. Onc. (1994) 12:553–559.
   PubMed Web of Science ®Google Scholar
• GERRITS CJH: SCHELLENS JHM, BURRIS H et al.: A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (hycamtin). Clin. Cancer Res. (1999) 5:69–75.
   Google Scholar
• HERBEN VM, ROSING H, TEN BOKKEL HUININK WW et al.: Oral topotecan: bioavailability and effect of food co-administration. Br. J. Cancer (1999) 80:1380–1386.
   Google Scholar
• O'CONNOR PM, KERRIGAN D, BERTRAND R, KOHN KW, POMMIER Y: 10,11-Methylenedioxycamptothecin, a topoisomerase I inhibitor of increased potency: DNA damage and correlation to cytotoxicity in human colon carcinoma (HT-29) cells. Cancer Comm. (1990) 2:395–400.
   PubMed Web of Science ®Google Scholar
• DALLAVALLE S, FERRARI A, BIASOTTI B, MERLINI L, PENCO S, GALLO G et al.: Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity. .1 Med. Chem. (2001) 44:3264–3274.
   Google Scholar
• JOSIEN H, BOM D, CURRAN DP, ZHENG YH, CHOU TC: 7-Silylcamptothecins (silatecans): a new family of camptothecin antitumor agents. Bioorg. Med. Chem. Lett. (1997) 7:3189–3194.
   Web of Science ®Google Scholar
• •This paper reports the first description and synthesis of a silatecan.
   Google Scholar
• LAVERGNE O, LESUEUR-GINOT L, RODAS FP, BIGG DCH: BN 80245: an E-ring-modified camptothecin with potent antiproliferative and topoisomerase I inhibitory activities. Bioorg. Med. Chem. Lett. (1997) 7:2235–2238.
   Web of Science ®Google Scholar
• •First report on the homolactone CPT.
   Google Scholar
• LAVERGNE O, LESUEUR-GINOT L, RODAS FP et al.: Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogs. J. Med. Chem. (1998) 41:5410–5419.
   PubMed Web of Science ®Google Scholar
• BAILLY C: Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs. Grit. Rev Onc. Hem. (2003) 45:91–108.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of hCPT and detailed description of topo I inhibition mechanism.
   Google Scholar
• DALLAVALLE S, MERFINI L, PENCO S, ZUNINO F: Perspectives in camptothecin development. Expert Opin. Ther. Patents (2002) 12:837–844.
   Web of Science ®Google Scholar
• SESSA C, HESS D, BASELGA J et al: Concerted escalation of dose and dosing-duration in a Phase I study of the oral camptothecin gimatecan (5T1481) in patients with advanced solid tumors. ASCO Annual Meeting (2002):Abst.386.
   Google Scholar
• KEIR ST, HAUSHEER F, LAWLESS AA, BIGNER DD, FRIEDMAN HS: Therapeutic activity of 7-[(2- trimethylsily0 ethyl)]-20 (5)-camptothecin [karenitecin] against central nervous system tumor-derived xenografts in athymic mice. Cancer Chemo. Pharm. (2001) 48:83–87.
   PubMed Web of Science ®Google Scholar
• SCHILSKY R, HAUSHEER F, BERTUCCI D, BERGHORN E, KINDLER H, RATAIN M: Phase I trial of karenitecin (KT) administered intravenously daily for five consecutive days in patients with advanced solid tumors using accelerated dose titration. ASCO Annual Meeting (2000):Abst.758.
   Google Scholar
• BOM D, CURRAN DP, CHAVAN AJ et aL: Novel A,B,E-ring-modified camptothecins displaying high lipophilicity and markedly improved human blood stabilities. Med. Chem. (1999) 42:3018–3022.
   Web of Science ®Google Scholar
• DU W, GABARDA AE, BOM D, CURRAN DP: The combinatorial synthesis of racemic homosilatecan libraries via a cascade radical annulation. In: The Carnptothecins. Unfolding their Anti-cancer potential. Liehr JG, Giovanella BC, Verschraegen CF (Eds), New York Academy of Sciences, USA (2000) 922:317–319.
   Google Scholar
• DU W, KASKAR B, BLUMBERGS P, SUBRAMANIAN PK, CURRAN D: Semisynthesis of DB-67 and other silatecans from camptothecin by thiol-promoted addition of silyl radicals. Bioorg. Med. Chem. (2003) 11:451–458.
   PubMed Web of Science ®Google Scholar
• BOM D, CURRAN DE KRUSZEWSKI S, ZIMMER SG, STRODE JT, KOHLHAGEN G: The novel silatecan 7-tert-butyldimethylsily1-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J Med. Chem. (2000) 43:3970–3980.
   PubMed Web of Science ®Google Scholar
• POLLACK IF, ERFF M, BOM D, BURKE TG, STRODE JT, CURRAN DP: Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation M vitro and in vivo. Cancer Res. (1999) 59:4898–4905.
   PubMed Web of Science ®Google Scholar
• BURKE TG (PI.): The development of a liposomal formulation of highly lipophilic 7-t-butyldimethylsily1-10-hydroxycamptothecin (db67). National Cancer Institute RAID Project.
   Google Scholar
• VAN HATTUM AH, PINEDO HM, SCHLUPER HMM, HAUSHEER FH, BOVEN E: New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int. J Cancer (2000) 88:260–266.
   PubMed Web of Science ®Google Scholar
• VAN HATTUM AH, SCHLUPER HMM, HAUSHEER FH, PINEDO HM BOVEN E: Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance. Int. J. Cancer (2002) 100:22–29.
   PubMed Web of Science ®Google Scholar
• MALIEPAARD M, VAN GASTELEN MA. TOHGO A et al.: Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using nonsubstrate drugs or the BCRP inhibitor GF 120918. Clin. Cancer Res. (2001) 7:935–941.
   Google Scholar
• ALLEN JD, SCHINKEL AH: Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol. Cancer Therap. (2002) 1:427–434.
   PubMed Web of Science ®Google Scholar
• THOMPSON P, BERG S, GURURANGAN S et al.: A Phase I study of karenitecin in children. AACR Annual Meeting (2002):Abstr.2748.
   Google Scholar